Onco Actu du 1er octobre 2018

	2.11 Etiologie - Alimentation
More Evidence That Nutrition Studies Don’t Always Add Up [NY Times] Data dredging is fairly common in health research, and especially in studies involving food. It is one reason contradictory nutrition headlines seem to be the norm: One week coffee, cheese and red wine are found to be protective against heart disease and cancer, and the next week a new crop of studies pronounce that they cause it.
	4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma [FDA] The ClonoSEQ assay is an in vitro diagnostic that uses multiplex PCR and NGS to identify and quantify certain gene sequences in DNA extracted from bone marrow from patients with ALL or multiple myeloma.
	5.10 Traitements - Essais
Clinical Trials: FDA Releases Two Draft Guidances [RAPS] The US Food and Drug Administration (FDA) on Friday unveiled two draft guidances focused on adaptive clinical trial designs and master protocols for cancer treatment trials.
	5.12 Immunothérapies
A Patient-partnered Genomics Study Identifies Immunotherapy as Potential Treatment for a Rare Cancer [AACR] Our work suggests that patients with angiosarcoma of HFNS, which comprises the largest demographic of people affected by angiosarcoma, have a high mutational burden and UV light signature, and therefore may respond to checkpoint inhibition.
Cancer Immunotherapy Conference in New York City Features Latest Research on Response, Resistance, New Approaches to Treatment [AACR] However, such responses are seen in only a fraction of patients, and many patients develop resistance to these treatments. There is a need for continued research and innovation so that more patients may benefit from the promise of cancer immunotherapy.
	5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
Loyola is working on a new and improved CAR-T product, looking to overcome high-frequency side effects [EndPoints] Up until now, Loyola has been using the CAR-T drugs on the market from Novartis and Gilead/Kite. But once it starts up its own manufacturing operation, it plans to make it available in Chicago and “beyond.”
	5.12.6 Immunothérapies - AMM
FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma [Sanofi] Libtayo is the third anti-PD-1 approved in the U.S.
FDA approves first treatment for advanced form of the second most common skin cancer [FDA] The safety and efficacy of Libtayo was studied in two open label clinical trials. A total of 108 patients (75 with metastatic disease and 33 with locally-advanced disease) were included in the efficacy evaluation.
A speedy FDA offers lightning review and quick OK for the latest PD-1 from Regeneron and Sanofi [EndPoints] The drug will be sold as Libtayo for advanced cutaneous squamous cell carcinoma. Investigators came up with a 46.3% ORR for advanced CSCC in their key study and plan to sell the therapy with a wholesale acquisition cost of $9,100 per three-week treatment cycle.
	5.12.7 Immunothérapies - vaccins
New Cancer Vaccine Shows Early Promise for Patients with HER2-positive Cancers Bacterial Therapy Tolerable, Shows Early Promise in Patients With Advanced Solid Tumors [AACR] Janku and colleagues evaluated the intratumoral injection of C. novyi-NT spores in an open-label, first-in-human study. Between November 2013 and April 2017, the researchers enrolled 24 patients with treatment-refractory solid tumors, with 15 patients having sarcoma, seven patients having diverse carcinoma, and two patients having melanoma.
	5.3.4 Traitements - AMM (FDA, EMA,...)
Pfizer's once-failed Vizimpro rebounds with targeted lung cancer approval [FiercePharma] The go-ahead comes more than a year after Pfizer trotted out positive phase 3 results for the drug at 2017’s American Society of Clinical Oncology (ASCO) annual meeting. Data showed that Vizimpro had beaten out an in-class rival, AstraZeneca’s Iressa, at delaying cancer growth in newly diagnosed patients, paring down the risk of progression or death by 41%.
	6. Lutte contre les cancers
Tired of male-dominated meetings, leading cancer conference makes nearly all of its speakers women [Science] At the Frontiers in Cancer Research meeting early next month, 23 of the 28 invited speakers—or 82%—are women.
	6.12 Ethique
Sloan Kettering Executive Turns Over Windfall Stake in Biotech Start-Up [NY Times] The move to hand over his stake is one of several steps now underway as the cancer center tries to contain a crisis that has already led to the resignation of its chief medical officer and a review of its conflict-of-interest policies.
A Message to All Employees [MSK] Effective immediately, we have implemented a moratorium on appointments of MSK board members to serve on the boards of MSK start-ups or to make any direct investments in them.
	6.14 Prix Nobel
2018 Nobel Prize in Physiology or Medicine jointly to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation [Nobel Prize] Allison and Honjo showed how different strategies for inhibiting the brakes on the immune system can be used in the treatment of cancer. The seminal discoveries by the two Laureates constitute a landmark in our fight against cancer.
	6.5 Médecines alternatives/complémentaires
The Risk of Alternative Cancer Treatments [NY Times] Avoiding evidence-based treatments in favor of untested ones can contribute to higher death rates, a Yale study found.
	6.8 Communication
Serena Williams covers Divinyls hit for breast cancer awareness [The Guardian] Tennis star strips off and sings I Touch Myself to remind women to self-check.
	6.9 Controverses
Cochrane ousted researcher over improper use of letterhead, board co-chair says [STAT] Gøtzsche was “baselessly undermining Cochrane’s credibility and independence,” Koster said Thursday. At one point, he apologized, she said, which the board felt was a good sign. But earlier this year, a physician expressed concerns that Gøtzsche was using Cochrane letterhead in correspondence that didn’t reflect Cochrane views.